Background/Objectives: Molnupiravir (MOV), an oral antiviral COVID-19 treatment, was
introduced in the Czech Republic in December 2021 for COVID-19 patients at a high risk of …

Objective To assess the real-world effectiveness of molnupiravir (MOL) in reducing the need
for hospitalization in at-risk, non-hospitalized patients with confirmed COVID-19. Methods A …

Real-life experience of molnupiravir treatment is lacking, especially in people hospitalized
for underlying diseases not related to COVID-19. We conducted a retrospective analysis …

During the current pandemic, the gap between fundamental research and clinical practice
has been narrowing at a faster pace than ever before. While clinical trials play the main role …

Introduction Molnupiravir (MOV) is an oral antiviral for the treatment of individuals with mild-
to-moderate COVID-19 and at high risk of progression to severe disease. Our objective was …

Background The majority of available data on molnupiravir come from an unvaccinated
COVID-19 population. Therefore, we conducted this meta-analysis to integrate evidence …

Introduction: The coronavirus disease 2019 (COVID-19) pandemic started in March 2020.
Since then, there has been an urgent need for effective therapeutic methods to manage the …

Methods The surveillance data were collected from December 27, 2021, to May 2, 2023. All
reported adverse events were collected for safety analysis. Adverse drug reactions (ADRs) …

Background Molnupiravir is an oral antiviral drug that received Emergency Use
Authorization in three countries for the treatment of mild COVID-19. The aim of this …

Purpose Molnupiravir is an oral antiviral agent authorized for emergency use to treat mild to
moderate cases of coronavirus disease 2019 (COVID-19) in adults at high risk for …